Skip to main content

Leadiant Shows Rare Dedication to Patients With Recent FDA Approval of Revcovi

By Uncategorized

Leadiant Biosciences, Inc. formerly known as Sigma-Tau Pharmaceuticals, recently received FDA approval for Revcovi®, which provides improved treatment for patients living with ADA-SCID, better known as “Bubble Boy Disease.” The journey that lead to Revcovi is a prime example of Leadiant’s steadfast dedication to their patients and their rare disease portfolio.

Read More